Treats hypertension. ANDA 212317, held by Glenmark Pharms Ltd. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 212317 (Diltiazem Hydrochloride), held by Glenmark Pharms Ltd, was first approved by FDA on Mar 22, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem Hydrochloride Extended-Release Capsules (Twice-a-Day Dosage) are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medications, such as diuretics.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 22, 2021 | Original application | Approved |
| Diltiazem Hydrochloride60MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride90MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters